Marker Therapeutics Inc./$MRKR
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
- Ticker
- $MRKR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 5
- Headquarters
- Houston, United States
- Website
- markertherapeutics.com
MRKR Metrics
BasicAdvanced
$16M
-
-$0.47
1.51
-
Price and volume
Market cap
$16M
Beta
1.51
52-week high
$2.46
52-week low
$0.87
Average daily volume
164K
Financial strength
Current ratio
6.027
Quick ratio
5.351
Profitability
Gross margin (TTM)
-148.28%
Net profit margin (TTM)
-245.51%
Operating margin (TTM)
-267.95%
Effective tax rate (TTM)
0.17%
Revenue per employee (TTM)
$710,000
Management effectiveness
Return on assets (TTM)
-40.47%
Return on equity (TTM)
-76.87%
Valuation
Price to revenue (TTM)
5.01
Price to book
1.3
Price to tangible book (TTM)
1.3
Price to free cash flow (TTM)
-1.821
Free cash flow yield (TTM)
-54.91%
Free cash flow per share (TTM)
-0.522
Growth
Revenue change (TTM)
-15.11%
Earnings per share change (TTM)
-65.55%
3-year revenue growth (CAGR)
-1.89%
3-year earnings per share growth (CAGR)
-32.96%
10-year earnings per share growth (CAGR)
-36.64%
What the Analysts think about MRKR
Analyst ratings (Buy, Hold, Sell) for Marker Therapeutics Inc. stock.
Analyst projections of the future price of Marker Therapeutics Inc. stock.
MRKR Financial Performance
Revenues and expenses
MRKR Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.